Literature DB >> 16782959

Thiopurine methyltransferase screening before azathioprine therapy.

V Gauba, M Saldanha, C Vize, G M Saleh.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16782959      PMCID： PMC1857159          DOI： 10.1136/bjo.2006.092700

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN： 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  10 in total

1.  Thiopurine methyltransferase levels should be measured before commencing patients on azathioprine.

Authors:  A P Jackson; A G Hall; J McLelland
Journal:  Br J Dermatol       Date:  1997-01       Impact factor: 9.302

2.  Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.

Authors:  W E Evans; Y Y Hon; L Bomgaars; S Coutre; M Holdsworth; R Janco; D Kalwinsky; F Keller; Z Khatib; J Margolin; J Murray; J Quinn; Y Ravindranath; K Ritchey; W Roberts; Z R Rogers; D Schiff; C Steuber; F Tucci; N Kornegay; E Y Krynetski; M V Relling
Journal:  J Clin Oncol       Date:  2001-04-15       Impact factor: 44.544

3.  Measurement of thiopurine methyl transferase activity guides dose-initiation and prevents toxicity from azathioprine.

Authors:  Christiaan Sies; Christopher Florkowski; Peter George; Richard Gearry; Murray Barclay; James Harraway; Linda Pike; Trevor Walmsley
Journal:  N Z Med J       Date:  2005-02-25

4.  Screening for azathioprine toxicity: a pharmacoeconomic analysis based on a target case.

Authors:  S M Tavadia; P R Mydlarski; M D Reis; N Mittmann; P H Pinkerton; N Shear; D N Sauder
Journal:  J Am Acad Dermatol       Date:  2000-04       Impact factor: 11.527

Review 5.  Thiopurine methyltransferase: should it be measured before commencing thiopurine drug therapy?

Authors:  Jeremy Sanderson; Azhar Ansari; Tony Marinaki; John Duley
Journal:  Ann Clin Biochem       Date:  2004-07       Impact factor: 2.057

6.  Rheumatoid arthritis: treatment with azathioprine (IMURAN (R)). Clinical side-effects and laboratory abnormalities.

Authors:  J K Whisnant; J Pelkey
Journal:  Ann Rheum Dis       Date:  1982       Impact factor: 19.103

7.  Cost-effectiveness of thiopurine methyltransferase genotype screening in patients about to commence azathioprine therapy for treatment of inflammatory bowel disease.

Authors:  J Winter; A Walker; D Shapiro; D Gaffney; R J Spooner; P R Mills
Journal:  Aliment Pharmacol Ther       Date:  2004-09-15       Impact factor: 8.171

Review 8.  Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine.

Authors:  G P R Clunie; L Lennard
Journal:  Rheumatology (Oxford)       Date:  2003-10-17       Impact factor: 7.580

9.  Erythrocyte thiopurine methyl transferase assessment prior to azathioprine use in the UK.

Authors:  S A Holme; J A Duley; J Sanderson; P A Routledge; A V Anstey
Journal:  QJM       Date:  2002-07

10.  Pharmacoeconomic analysis of thiopurine methyltransferase polymorphism screening by polymerase chain reaction for treatment with azathioprine in Korea.

Authors:  K-T Oh; A H Anis; S-C Bae
Journal:  Rheumatology (Oxford)       Date:  2003-08-15       Impact factor: 7.580
  10 in total
  1 in total

1.  Implementation of TPMT testing.

Authors:  Lynne Lennard
Journal:  Br J Clin Pharmacol       Date:  2014-04       Impact factor: 4.335
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.